RitaNandaMD

PubMed

• 11 citations
  Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer tri...
  M Marczyk, A Mrukwa, C Yau, D Wolf, Y-Y Chen
  Annals of Oncology. 2022-08-01
• 516 citations
  Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.
  Sylvia Adams, Peter Schmid, Hope S. Rugo, Eric P. Winer, Delphine Loirat
  Annals of Oncology. 2019-03-01
• 42 citations
  Atezolizumab for the treatment of breast cancer.
  Sangeetha M. Reddy, Emma Carroll, Rita Nanda
  Expert Review of Anticancer Therapy. 2020-02-27

Journal Articles

• Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy with Disease Recurrence in Patients with Triple-Negative Breast Cancer  
  Rita Nanda, Carla Falkson, Filipa C Lynce, Claudine Isaacs, Marcelo Blaya, Elisavet Paplomata, Radhika Walling, Reshma Mahtani, Tarah J Ballinger, Kathy D Miller, Brya..., JAMA Oncology
• Pembrolizumab Monotherapy for Previously Untreated, PD-L1-Positive, Metastatic Triple-Negative Breast Cancer: Cohort B of the Phase II KEYNOTE-086 Study  
  M C Liu, R Nanda, H S Rugo, E P Winer, S Adams, Annals of Oncology
• Immune Checkpoint Inhibition for Triple-Negative Breast Cancer  
  Saha P and Nanda R, Oncology and Hematology Review, 1/8/2016
• Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase 1b KEYNOTE-012 Study  
  Nanda R, Chow LQM, Dees EC, Berger R, Gupta S, Geva R, Pusztai L, Pathiraja K, Aktan G, Cheng JD, Karantza V, Buisseret L, J Clin Oncol, 1/2/2016
• TBCRC 019: phase II trial of nab-PAC with/without the anti-death receptor 5 monoclonal antibody tigatuzumab in patients with triple negative breast cancer  
  Forero-Torres A, Varley KE, Abramson V, Li Y, Vaklavas C, Lin NU, Liu MC, Rugo HS, Nanda R, Stroniolo AM, Traina TA, Patil S, Van Poznak C, Nangia JR, Irvin WJ Jr, Hel..., Clin Cancer Res, 1/16/2015
• Significance of Circulating Tumor Cells in metastatic triple negative breast cancer patients within a randomized, phase II trial: TBCRC 019  
  Paoletti C, Li Y, Muniz MC, Kidwell KM, Aung K, Thomas DG, Brown M, Abramson V, Irvin WJ Jr, Lin NU, Liu MC, Nanda R, Nangia JR, Storniolo AM, Traina TA, Vaklavas C, V..., Clin Cancer Res, 1/16/2015
• The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer  
  DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, ..., Clin Cancer Res, 1/1/2015
• Surgical Patterns of Care in Patients with Invasive Breast Cancer Treated with Neoadjuvant Systemic Therapy and Breast Magnetic Resonance Imaging: Results of a Seconda...  
  McGuire KP, Hwang ES, Cantor A, Golshan M, Meric-Bernstam F, Horton JK, Nanda R, Amos KD, Forero A, Hudis CA, Meszoely I, De Los Santos JF, Ann Surg Oncol, 1/1/2015
• TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases  
  Anders C, Deal AM, Abramson V, Liu MC, Storniolo AM, Carpenter JT, Puhalla S, Nanda R, Melhem-Bertrandt A, Lin NU, Kelly Marcom P, Van Poznak C, Stearns V, Melisko M, ..., Breast Cancer Res Treat, 1/8/2014
• Gene expression of peripheral blood cells reveals pathways downstream of glucocorticoid receptor antagonism and nab-paclitaxel treatment  
  Maranville JC, Nanda R, Fleming GF, Skor MN, Di Rienzo A, Conzen SD, Pharmacogenet Genomics, 1/3/2014
• Magnetic Resonance Imaging as a Predictor of Pathologic Response in Patients Treated with Neoadjuvant Systemic Treatment for Operable Breast Cancer (TBCRC 017)  
  J De Los Santos, Jennifer, A Cantor, K Amos, A Forero, M Golshan, J Horton, C Hudis, N Hylton, K McGuire, F Meric-Bernstam, I Meszoely, R Nanda, S Hwang, Cancer, 1/15/2013
• TBCRC 006: A multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy, and without chemotherapy in patients with HER2 overexpressing b...  
  MF Rimawi, IA Mayer, A Forero, R Nanda, MP Goetz, AA Rodriguez, AC Pavlick, T Wang, SG Hilsenbeck, C Gutierrez, R Schiff, CK Osborne, JC Chang, J Clin Oncol, 1/10/2013
• A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastaticbreast cancer  
  Ma CX, Suman VJ, Goetz M, Haluska P, Moynihan T, Nanda R, Olopade O, Pluard T, Guo Z, Chen HX, Erlichman C, Ellis MJ, Fleming GF, Breast Cancer Res Treat, 1/1/2013
• The role of tumor-associated macrophages in breast cancer progression  
  Obeid E, Nanda R, Fu YX, Olopade OI, Int J Oncol, 1/1/2013
• Phase II Trial of Temsirolimus in Patients with Metastatic Breast Cancer  
  Fleming GF, Ma CX, Huo D, Sattar H, Tretiakova M, Lin L, Hahn OM, Olopade O, Nanda R, Hoffman PC, Naughton MJ, Pluard T, Conzen SD, Ellis MJ, Breast Cancer Res Treat, 1/1/2012
• “Targeting” triple-negative breast cancer: The lessons learned from BRCA1-associated breast cancers  
  Nanda R, Seminars in Oncology, 1/1/2011
• Population Differences in Breast Cancer: Survey in Indigenous African Women Reveal Overrepresentation of Triple Negative Breast Cancer  
  Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, Zhang B, Grushko T, Zhang C, Oluwasola O, Malaka D, Malami S, Odetunde A, Adeoye AO, Iyare F, Falusi A, Per..., JCO, 1/24/2009
• Advances in Breast Cancer: Pathways to Personalized Medicine  
  Olopade OI, Grushko TA, Nanda R, Huo D, CCR, 1/15/2008
• Promoter methylation of Estrogen Receptor, BRCA1 and FANCF in Sporadic Breast Cancers  
  Wei M, Xu J, Dignam J, Nanda R, Sveen L, Fackenthal J, Grushko TA, Olopade OI, Breast Cancer Research Treatment, 1/12/2007
• Targeting the Human Epidermal Growth Factor Receptor 2 (HER2) in the Treatment of Breast Cancer: Recent Advances and Future Directions  
  Nanda R, RRCT, 1/1/2007
• A New Breast Tumor Intrinsic Gene List Identifies Novel Characteristics that are Conserved Across Microarray Platforms  
  Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, Sawyer LR, Wu J, Liu Y, Nanda R, Tretiakova M,..., BMC Genomics, 1/27/2006
• A Common Pattern of Promoter Hypermethylation in Lung and Breast Tumors  
  Shames DS, Girard L, Gao B, Sato M, Lewis CM, Shivapurkar N, Jiang A, Perou CM, Kim YH, Pollack JR, Fong KM, Lam CL, Wong M, Shyr Y, Nanda R, Olopade OI, Gerald W, Euh..., PLoS Medicine, 1/1/2006
• Genetic testing in an Ethnically Diverse Cohort of High Risk Women: A Comparative Analysis of BRCA1 and BRCA2 Mutations in American Families of European and African A...  
  Nanda R, Schumm LP, Cummings S, Fackenthal JD, Sveen L, Ademuyiwa F, Cobleigh M, Esserman L, Lindor NM, Neuhausen SL, Olopade OI, JAMA, 1/19/2005
• BRCA1 Promoter Methylation in Sporadic Breast Cancer is Associated with Reduced BRCA1 Copy Number and Chromosome 17 Aneusomy  
  Wei M, Grushko TA, Dignam J, Hagos F, Nanda R, Sveen L, Xu J, Fackenthal J, Tretiakova M, Das S, Olopade OI, Cancer Research, 1/1/2005
• Join now to see all

Books/Book Chapters

• Cancer Biology Review: A Case Based Approach 
  Chapter: Fundamental of DNA Damage and Repair 
  P Connell and R NandaEditors: W Stadler.Edition 1st,2013
• Cancer Medicine 
  Chapter: Recurring Chromosome Rearrangements in Human Cancer 
  DA Levitan, R Nanda, JD Rowley, OI OlopadeEditors: J Holland and E Frei.Edition 6th,2003
• Pocket Primary Care 
  Chapter: Chronic Fatigue Syndrome 
  Nanda REditors: LK Halasyamani and BP Lucas.Edition 1st,2001

Lectures

• Advances in Triple-Negative Breast Cancer 
  Cancun, Mexico - 1/1/2016
• Immunotherapy for the Treatment of Triple-Negative Breast Cancer 
  Royal College of Physicians, London, United Kingdom - 1/1/2016
• Immunotherapy in Oncology 
  Cancun, Mexico - 1/1/2016
• Immunotherapy for Breast Cancer—Hype or Hope? 
  Huntington Beach, CA - 1/1/2015
• Neoadjuvant and Adjuvant Therapy and the Treatment of Early Stage Breast Cancer 
  Omaha, NE - 1/1/2015
• Immunotherapy for Breast Cancer 
  Chicago, IL, 2015; San Francisco, CA, 2015; Naples, Italy, 2015 - 1/1/2015
• Neoadjuvant Chemotherapy for Breast Cancer 
  Chicago, IL - 1/1/2015
• Breast Cancer Updates 
  Chicago, IL - 1/1/2015
• Neoadjuvant clinical trials for breast cancer 
  1/1/2015
• “Targeting” triple-negative breast cancer 
  Dyer, IN, 2015; New Haven, CT, 2015 - 1/1/2015
• A Phase Ib Study of Pembrolizumab (MK-3475) in Patients With Advanced Triple-Negative Breast Cancer 
  San Antonio, TX - 1/1/2014
• Neoadjuvant chemotherapy for triple-negative breast cancer 
  1/1/2014
• A Randomized Phase I Trial of Nanoparticle Albumin Bound Paclitaxel (nab-paclitaxel, Abraxane®) With or Without Mifepristone for Advanced Breast Cancer 
  1/1/2013
• Genetics and Breast Cancer: Risk Assessment and Genetic Testing 
  Bellevue, WA - 1/1/2013
• The alternatively activated macrophage phenotype correlates with aggressive histopathologic features and poor clinical outcome in early stage breast cancer 
  Buonas, Switzerland - 1/1/2013
• A Randomized Phase I Trial of Nanoparticle Albumin Bound Paclitaxel (Abraxane®) With or Without Mifepristone for Advanced Breast Cancer 
  San Antonio, TX - 1/1/2013
• Neoadjuvant chemotherapy in the very young patient 
  1/1/2013
• Case Studies in HER-2 Positive Breast Cancer 
  1/1/2013
• Triple-negative metastatic breast cancer 
  Chicago, IL - 1/1/2012
• Breast Cancer 
  1/1/2012
• Neoadjuvant chemotherapy for HER2 positive breast cancer 
  1/1/2012
• Neoadjuvant Chemotherapy 
  1/1/2012
• Breast Cancer Clinical Updates from the Best of ASCO 
  1/1/2011
• Tumor-associated macrophages and breast cancer 
  1/1/2010
• Breast Cancer Highlights: An Interdisciplinary Perspective 
  1/1/2010
• Join now to see all

Other

• Immunotherapy for triple-negative breast cancer 
  Numerous Outlets
  1/1/2016
• Interview on the role of clinical trials for breast cancer 
  WebMD
  1/1/2013
• Interview on treatment and research for breast cancer 
  ABC 7 News
  1/1/2012
• Interview on triple-negative breast cancer 
  CBS Chicago News
  1/1/2011
• Interview on HER2 positive metastatic breast cancer 
  Chicago Sun Times
  1/1/2011
• The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with muta... 
  Nanda R and Olopade OI, Breast Diseases: A yearbook
  1/1/2003
• Join now to see all